HUS2300027I1 - BCMA (CD269/TNFRSF17)-kötõ fehérjék - Google Patents

BCMA (CD269/TNFRSF17)-kötõ fehérjék

Info

Publication number
HUS2300027I1
HUS2300027I1 HUS2300027C HUS2300027C HUS2300027I1 HU S2300027 I1 HUS2300027 I1 HU S2300027I1 HU S2300027 C HUS2300027 C HU S2300027C HU S2300027 C HUS2300027 C HU S2300027C HU S2300027 I1 HUS2300027 I1 HU S2300027I1
Authority
HU
Hungary
Prior art keywords
tnfrsf17
bcma
binding proteins
proteins
binding
Prior art date
Application number
HUS2300027C
Other languages
English (en)
Original Assignee
Sg1 2Ny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46148885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2300027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sg1 2Ny filed Critical Sg1 2Ny
Publication of HUS2300027I1 publication Critical patent/HUS2300027I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HUS2300027C 2011-05-27 2023-10-27 BCMA (CD269/TNFRSF17)-kötõ fehérjék HUS2300027I1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490732P 2011-05-27 2011-05-27
US201261647196P 2012-05-15 2012-05-15
EP18163942.8A EP3415531B1 (en) 2011-05-27 2012-05-24 Bcma (cd269/tnfrsf17) - binding proteins

Publications (1)

Publication Number Publication Date
HUS2300027I1 true HUS2300027I1 (hu) 2023-12-28

Family

ID=46148885

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18163942A HUE063461T2 (hu) 2011-05-27 2012-05-24 BCMA (CD269/TNFRSF17)-kötõ fehérjék
HUS2300027C HUS2300027I1 (hu) 2011-05-27 2023-10-27 BCMA (CD269/TNFRSF17)-kötõ fehérjék

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE18163942A HUE063461T2 (hu) 2011-05-27 2012-05-24 BCMA (CD269/TNFRSF17)-kötõ fehérjék

Country Status (36)

Country Link
US (1) US20140105915A1 (hu)
EP (4) EP3415531B1 (hu)
JP (5) JP6263467B2 (hu)
KR (1) KR101972446B1 (hu)
CN (2) CN103562225B (hu)
AR (1) AR086579A1 (hu)
AU (1) AU2012264890C1 (hu)
BR (1) BR112013028779B8 (hu)
CA (1) CA2833820C (hu)
CL (2) CL2013003373A1 (hu)
CO (1) CO6811809A2 (hu)
CR (1) CR20130624A (hu)
DK (1) DK3415531T3 (hu)
DO (1) DOP2013000280A (hu)
EA (2) EA028220B1 (hu)
ES (1) ES2953190T3 (hu)
FI (2) FI3415531T3 (hu)
FR (1) FR23C1032I1 (hu)
HR (1) HRP20231066T1 (hu)
HU (2) HUE063461T2 (hu)
IL (2) IL228784B (hu)
LT (1) LT3415531T (hu)
MA (1) MA35208B1 (hu)
MX (1) MX351069B (hu)
MY (1) MY177970A (hu)
NL (1) NL301241I2 (hu)
PE (1) PE20141045A1 (hu)
PL (1) PL3415531T3 (hu)
PT (1) PT3415531T (hu)
RS (1) RS64791B1 (hu)
SG (1) SG194176A1 (hu)
SI (1) SI3415531T1 (hu)
TW (2) TWI609883B (hu)
UY (1) UY34101A (hu)
WO (1) WO2012163805A1 (hu)
ZA (1) ZA201308635B (hu)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0013391B8 (pt) 1999-08-17 2021-05-25 Apotech R&D S A uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
DK3415531T3 (da) * 2011-05-27 2023-09-18 Glaxo Group Ltd Bcma (cd269/tnfrsf17)-bindende proteiner
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CA2869562C (en) 2012-04-11 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US10189906B2 (en) 2012-11-01 2019-01-29 Max-Delrück-Centrum Für Molekulare Medizin Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2762496A1 (en) * 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2953972B1 (en) * 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US10126301B2 (en) * 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
GB2513405A (en) * 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
CA2916521C (en) 2013-07-09 2023-03-07 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
EP3102681B1 (en) 2014-02-07 2023-10-04 McMaster University Trifunctional t cell-antigen coupler and methods and uses thereof
US10752665B2 (en) 2014-02-27 2020-08-25 Ucl Business Ltd April variants
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
SG11201608415QA (en) 2014-04-30 2016-11-29 Max Delbrück Ct Für Molekulare Medizin In Der Helmholtz Gemeinschaft Humanized antibodies against cd269 (bcma)
BR112016028644B1 (pt) 2014-06-06 2019-12-03 Bluebird Bio Inc Método in vitro ou ex vivo para fabricar células t, composição compreendendo um agente de crioproteção e uma população de células efetoras imunes e usos terapêuticos dadita composição
CN106687483B (zh) 2014-07-21 2020-12-04 诺华股份有限公司 使用人源化抗-bcma嵌合抗原受体治疗癌症
AR101829A1 (es) 2014-07-21 2017-01-18 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR20230149327A (ko) 2014-09-17 2023-10-26 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
AU2015360845B2 (en) 2014-12-12 2020-11-26 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN114773476A (zh) * 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
CN107980046B (zh) * 2015-04-13 2021-12-24 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2992797A1 (en) * 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN108474793A (zh) * 2015-10-30 2018-08-31 葛兰素史密斯克莱知识产权发展有限公司 预后方法
WO2017083511A1 (en) * 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-bcma polypeptides and proteins
EP3380620A1 (en) 2015-11-23 2018-10-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
MY197345A (en) 2015-11-25 2023-06-14 Visterra Inc Antibody molecules to april and uses thereof
WO2017093942A1 (en) * 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
ES2898329T3 (es) 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
WO2017143069A1 (en) 2016-02-17 2017-08-24 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
BR112018067679A2 (pt) 2016-03-04 2019-01-15 Novartis Ag células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
HUE060645T2 (hu) 2016-04-01 2023-04-28 Kite Pharma Inc Kiméra receptorok és felhasználásuk módszerei
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
CU20180120A7 (es) 2016-04-01 2019-05-03 Kite Pharma Inc Moléculas de unión a bcma
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
KR20190053835A (ko) 2016-06-21 2019-05-20 테네오바이오, 인코포레이티드 Cd3 결합 항체
CA3032581A1 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
KR20190046854A (ko) * 2016-09-14 2019-05-07 얀센 바이오테크 인코포레이티드 Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
KR20230035706A (ko) 2016-09-14 2023-03-14 테네오원, 인코포레이티드 Cd3 결합 항체
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
KR20230052309A (ko) 2016-12-21 2023-04-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
AU2018209012A1 (en) * 2017-01-23 2019-09-12 Crage Medical Co., Limited BCMA-targeting antibody and use thereof
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN117357638A (zh) 2017-02-17 2024-01-09 弗雷德哈钦森癌症中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
JP7115758B2 (ja) 2017-02-28 2022-08-09 アッフィメッド・ゲー・エム・ベー・ハー Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CN108624549B (zh) * 2017-03-23 2020-11-20 上海奥浦迈生物科技有限公司 一种cho dg44培养基及其应用
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
KR20200005596A (ko) 2017-05-12 2020-01-15 크리스퍼 테라퓨틱스 아게 세포를 엔지니어링하기 위한 물질 및 방법, 및 면역-종양학에서의 그의 용도
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
AU2018283039A1 (en) 2017-06-14 2019-11-14 Dana-Farber Cancer Institute, Inc. B-cell maturation antigen (BCMA)-directed nanoparticles
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
SG11201912774RA (en) 2017-06-20 2020-01-30 Teneobio Inc Anti-bcma heavy chain-only antibodies
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
SG11202000499RA (en) * 2017-08-01 2020-02-27 Medimmune Llc Bcma monoclonal antibody-drug conjugate
CN111094353A (zh) 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
JP2020533382A (ja) * 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
CA3075716A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
BR112020006248A8 (pt) * 2017-09-29 2023-03-21 Mogam Inst Biomedical Res Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer
CA3078637A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
MX2020003856A (es) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc Proteinas de union a antigenos de maduracion de celulas b.
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
SG11202003866QA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
GB201720426D0 (en) * 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
US20220298254A1 (en) 2017-11-01 2022-09-22 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
CA3088095A1 (en) 2017-11-15 2019-05-23 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
WO2019133799A1 (en) * 2017-12-29 2019-07-04 University Of Florida Research Foundation Monoclonal antibodies targeting microtubule-binding domain of tau protein
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
TWI800854B (zh) 2018-02-01 2023-05-01 大陸商信達生物製藥（蘇州）有限公司 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
JP6968389B2 (ja) * 2018-02-01 2021-11-17 南京馴鹿医療技術有限公司 Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
AU2019247229A1 (en) * 2018-04-05 2020-10-15 Novartis Ag Trispecific binding molecules against cancers and uses thereof
CN110372796B (zh) * 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
WO2019198051A2 (en) 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CR20200571A (es) 2018-06-01 2021-01-18 Novartis Ag Moléculas de únion contra bcma y usos de las mismas
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
BR112020025048A2 (pt) 2018-06-13 2021-04-06 Novartis Ag Receptores de antígeno quimérico de bcma e usos dos mesmos
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
EP3823664A1 (en) 2018-07-19 2021-05-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US20210332145A1 (en) * 2018-10-09 2021-10-28 Single Cell Technology, Inc. Anti-bcma antibodies
CN112955748A (zh) 2018-10-31 2021-06-11 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2022523100A (ja) * 2019-02-01 2022-04-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ベランタマブマフォドチンおよび抗ｏｘ４０抗体を含むがんの併用治療ならびにその使用および方法
CA3124935A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
MX2021013359A (es) 2019-04-30 2022-01-31 Crispr Therapeutics Ag Terapia de celulas alogénicas de neoplasias malignas de células b usando células t modificadas genéticamente dirigidas a cd19.
JP2022533400A (ja) 2019-05-20 2022-07-22 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
US20220211861A1 (en) * 2019-05-22 2022-07-07 The Board of Trustees of the Leland Staford Junior University Drug conjugates and methods of using same
KR20220016188A (ko) * 2019-05-31 2022-02-08 메디뮨 엘엘씨 병용 요법
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN112585168B (zh) 2019-07-30 2022-04-15 上海翰森生物医药科技有限公司 抗bcma抗体、其抗原结合片段及其医药用途
EP4010372A2 (en) * 2019-08-06 2022-06-15 GlaxoSmithKline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
CN112409482B (zh) * 2019-08-20 2022-08-26 杭州尚健生物技术有限公司 Bcma抗体
CN112646032A (zh) 2019-10-10 2021-04-13 苏州亲为药业有限公司 靶向bcma的具有人猴交叉的人源化单克隆抗体
KR20220105664A (ko) 2019-11-26 2022-07-27 노파르티스 아게 Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도
AU2020390288A1 (en) * 2019-11-26 2022-05-26 Shanghai Epimab Biotherapeutics Co., Ltd. Antibodies to CD3 and BCMA, and bispecific binding proteins made therefrom
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4085076A4 (en) * 2020-01-03 2024-01-24 Biosion Inc ANTIBODIES BINDING TO BCMA AND THEIR USES
TW202128769A (zh) * 2020-01-03 2021-08-01 大陸商信立泰（成都）生物技術有限公司 結合bcma的抗體及其用途
CN111234020B (zh) * 2020-01-23 2020-10-23 和铂医药(苏州)有限公司 一种bcma结合蛋白及其制备方法和应用
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
CN113248611A (zh) * 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
WO2021228783A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceutica Nv Methods for treating multiple myeloma
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115850484A (zh) * 2020-06-18 2023-03-28 重庆精准生物技术有限公司 一种靶向cd70的单链抗体及其应用
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
KR20230058427A (ko) 2020-08-21 2023-05-03 노파르티스 아게 Car 발현 세포의 생체내 생성을 위한 조성물 및 방법
EP4237451A1 (en) 2020-11-02 2023-09-06 Hummingbird Bioscience Pte. Ltd. Bcma/taci antigen-binding molecules
KR20230143605A (ko) 2020-11-24 2023-10-12 노파르티스 아게 Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
US11965022B2 (en) 2020-12-31 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
TW202246351A (zh) * 2021-02-08 2022-12-01 美商恩格姆生物製藥公司 Htra1結合劑及其使用方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
EP4340851A1 (en) 2021-05-19 2024-03-27 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
CA3220227A1 (en) 2021-05-28 2022-12-01 Matthew Bruce Combination therapies for treating cancer
CN115521381A (zh) 2021-06-24 2022-12-27 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CA3225985A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023287827A2 (en) 2021-07-14 2023-01-19 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
CN117794954A (zh) 2021-08-03 2024-03-29 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和稳定同位素标记肽图谱方法
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
AU2022330406A1 (en) 2021-08-20 2024-03-07 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
WO2023057893A1 (en) 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023081754A1 (en) * 2021-11-04 2023-05-11 Dana-Farber Cancer Institute, Inc. Developing inducible cluster chimeric antigen receptor (ccar) constructs
WO2023104138A1 (zh) * 2021-12-09 2023-06-15 江苏先声药业有限公司 Bcma抗体及其应用
TW202342757A (zh) 2021-12-17 2023-11-01 美商薩那生物科技公司 經修飾副黏液病毒科附著醣蛋白
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023178357A1 (en) 2022-03-18 2023-09-21 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023232911A1 (en) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab Novel polypeptides
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
ES2195036T3 (es) 1995-12-22 2003-12-01 Bristol Myers Squibb Co Conectores de hidrazona ramificados.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN101371923B (zh) * 1999-08-17 2013-04-17 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
BRPI0013391B8 (pt) * 1999-08-17 2021-05-25 Apotech R&D S A uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
AR030612A1 (es) 2000-09-12 2003-08-27 Smithkline Beecham Corp Procedimiento e intermedios
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
CA2438682A1 (en) * 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2337986T3 (es) 2001-08-10 2010-05-03 Aberdeen University Dominios de union de antigenos de peces.
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
WO2005003156A1 (en) 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
EP1776385A1 (en) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
EP1836224A1 (en) * 2004-12-23 2007-09-26 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
WO2007011041A1 (ja) 2005-07-22 2007-01-25 Kyowa Hakko Kogyo Co., Ltd. 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
MY150643A (en) * 2006-06-22 2014-02-14 Genentech Inc Methods and compositions for targeting hepsin
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
AU2009204974A1 (en) * 2008-01-15 2009-07-23 F. Hoffmann-La Roche Ag Afucosylated antibodies against CCR5 and their use
PL2406284T3 (pl) * 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
WO2011108008A2 (en) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
WO2012066058A1 (en) * 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
DK3415531T3 (da) 2011-05-27 2023-09-18 Glaxo Group Ltd Bcma (cd269/tnfrsf17)-bindende proteiner
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма

Also Published As

Publication number Publication date
CL2016002585A1 (es) 2017-05-19
MX2013013942A (es) 2014-05-21
MY177970A (en) 2020-09-28
CN106279418A (zh) 2017-01-04
HUE063461T2 (hu) 2024-01-28
NZ616433A (en) 2016-04-29
JP7475515B2 (ja) 2024-04-26
IL255253A0 (en) 2017-12-31
AU2012264890A1 (en) 2013-05-09
TWI609883B (zh) 2018-01-01
FI3415531T3 (fi) 2023-09-07
WO2012163805A1 (en) 2012-12-06
CN103562225B (zh) 2016-09-28
SI3415531T1 (sl) 2023-12-29
JP2014520088A (ja) 2014-08-21
EP3693394A1 (en) 2020-08-12
EA201790330A1 (ru) 2018-02-28
TWI644924B (zh) 2018-12-21
SG194176A1 (en) 2013-12-30
EP3415531B1 (en) 2023-09-06
UY34101A (es) 2013-01-03
NL301241I1 (hu) 2023-09-13
FIC20230029I1 (fi) 2023-09-07
DOP2013000280A (es) 2014-04-30
JP2022033797A (ja) 2022-03-02
EP2714737A1 (en) 2014-04-09
NL301241I2 (nl) 2023-10-26
JP2018087190A (ja) 2018-06-07
AR086579A1 (es) 2014-01-08
ZA201308635B (en) 2021-05-26
CO6811809A2 (es) 2013-12-16
LT3415531T (lt) 2023-09-25
BR112013028779A2 (pt) 2017-08-01
US20140105915A1 (en) 2014-04-17
RS64791B1 (sr) 2023-11-30
EP4338754A2 (en) 2024-03-20
MX351069B (es) 2017-09-29
AU2012264890C1 (en) 2016-03-10
JP7018910B2 (ja) 2022-02-14
CA2833820C (en) 2019-10-29
JP6263467B2 (ja) 2018-01-17
CR20130624A (es) 2014-02-04
HRP20231066T1 (hr) 2023-10-27
JP7260621B2 (ja) 2023-04-18
EA201391457A1 (ru) 2014-04-30
JP2023085488A (ja) 2023-06-20
CA2833820A1 (en) 2012-12-06
EA028220B1 (ru) 2017-10-31
CL2013003373A1 (es) 2014-07-25
KR20140036272A (ko) 2014-03-25
IL228784A0 (en) 2013-12-31
TW201311722A (zh) 2013-03-16
PT3415531T (pt) 2023-09-12
MA35208B1 (fr) 2014-06-02
AU2012264890B2 (en) 2015-10-15
PE20141045A1 (es) 2014-09-10
CN103562225A (zh) 2014-02-05
BR112013028779B1 (pt) 2021-01-05
BR112013028779B8 (pt) 2021-04-20
ES2953190T3 (es) 2023-11-08
KR101972446B1 (ko) 2019-04-25
EP3415531A1 (en) 2018-12-19
TW201811831A (zh) 2018-04-01
JP2019147816A (ja) 2019-09-05
PL3415531T3 (pl) 2024-02-26
FR23C1032I1 (fr) 2023-10-13
IL228784B (en) 2018-03-29
DK3415531T3 (da) 2023-09-18

Similar Documents

Publication Publication Date Title
HUS2300027I1 (hu) BCMA (CD269/TNFRSF17)-kötõ fehérjék
HK1212711A1 (zh) 抗原結合蛋白
EP2555797A4 (en) TNF-ALPHA-BINDING PROTEINS
EP2649189A4 (en) TNF-ALPHA-BINDING PROTEINS
HK1208186A1 (en) Drug protein conjugates
HK1208187A1 (en) Drug protein conjugates
EP2638072A4 (en) FUSION PROTEINS FOR HIV THERAPY
IL221007A (en) Pharmaceutical combinations for antiviral therapy
SG10202100341XA (en) Npp1 fusion proteins
SG10201606218WA (en) Purified Proteins
HK1245104A1 (zh) Dna疫苗
HK1188608A1 (en) Dna expression construct dna
EP2737062A4 (en) BY NON-INFRARED LIGHT ACTIVATED PROTEINS
PL2394638T3 (pl) Nowe połączenia farmaceutyczne
HK1179164A1 (zh) 包含肉豆蔻酰氨基丙基二甲基苄基氯化銨的藥物製劑
EP2593472A4 (en) STEM PROTEINS
PL390148A1 (pl) Preparat przeciwtrądzikowy
GB201211286D0 (en) Novel biological factor
GB201007955D0 (en) Somatosatin fusion proteins
GB201009960D0 (en) Card holder
GB201003513D0 (en) Bespoke books
TWM385766U (en) Study card
TWM386305U (en) Card
PL119288U1 (pl) Laurka okolicznościowa
GB201011497D0 (en) Page marker